Pharma BD Deal Intelligence
EUROIMMUN became a cornerstone diagnostics asset — COVID-era windfall, kept through the PerkinElmer-to-Revvity split, no impairments, still launching new products in 2025
Full analysis, sources & comparables →PerkinElmer to acquire EUROIMMUN for approximately $1.3 billion, expanding into autoimmune and allergy diagnostics and adding infectious-disease capabilities,…
Cowen's Doug Schenkel called the deal 'attractively accretive' and 'a good use of capital'; Evercore's Ross Muken said it 'furthers management's push into…
PerkinElmer expected ~$0.28-$0.30 non-GAAP EPS accretion in 2018, with EUROIMMUN's ~19% five-year revenue CAGR providing growth uplift to PKI's diagnostics…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
PerkinElmer agreed to acquire EUROIMMUN, a German leader in autoimmune testing and emerging player in infectious disease/allergy diagnostics, for approximately $1.3B. EUROIMMUN was expected to generate ~$310M revenue in 2017 with five-year average revenue growth of 19%. The deal expanded PerkinElmer's diagnostics portfolio across reproductive health, autoimmune, infectious disease and allergy testing. Closed December 2017.
EUROIMMUN became a cornerstone diagnostics asset — COVID-era windfall, kept through the PerkinElmer-to-Revvity split, no impairments, still launching new products in 2025
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| PerkinElmer, Inc. / EUROIMMUN Medizinische Labordiagnostika AG (this deal) | 2017 | $1.3B | 88 |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| Vertex Pharmaceuticals Incorporated / Alpine Immune Sciences | 2024 | $4.9B | 78 |
| Roche Holding AG / Genentech, Inc. (Roche Group) | 2009 | $46.8B | 72 |
| Travere Therapeutics, Inc. / Everest Medicines Limited | 2026 | $1.1B | 72 |
| Amgen Inc. / Horizon Therapeutics plc | 2022 | $27.8B | 72 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
← Browse all deals · How we score deals
More: 2017 deals · Immunology deals